High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. (scientific article published on 12 June 2013)

Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta

Q24314389

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Q24525309

Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy

Q24655510

Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation

Q24657633

Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals

Q24795458

Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency.

Q24815984

The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322

Q73752235

Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4

Q80087943

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

Q26991848

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

Q27860488

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

Q28111910

CD20 (pan-B cell antigen) expression on bone marrow-derived T cells

Q28284264

Epigenetic regulation of HIV-1 latency by cytosine methylation

Q28475636

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

Q29619611

Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients

Q30449471

Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation

Q33508788

Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome

Q33521702

Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells

Q33807628

Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis

Q33864445

Combinatorial latency reactivation for HIV-1 subtypes and variants

Q33877492

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

Q33949316

Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli

Q34124009

A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs

Q34145909

Biochemical mechanisms of HIV induced T cell apoptosis

Q34225886

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Q34290545

Multiple importins function as nuclear transport receptors for the Rev protein of human immunodeficiency virus type 1.

Q34527028

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

Q34576803

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

Q34725556

Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals

Q34762506

The MYST family of histone acetyltransferases.

Q35070010

Death and Baxes: mechanisms of lymphotrophic cytokines

Q35129707

Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals

Q35666098

T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue.

Q35828841

CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef.

Q35868046

Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions

Q35882308

IL-7: maintaining T-cell memory and achieving homeostasis

Q36061053

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation

Q36409885

CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza.

Q36494486

CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells

Q36526710

Isolation of microarray-quality RNA from primary human cells after intracellular immunostaining and fluorescence-activated cell sorting

Q36770254

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

Q36891848

Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells

Q37039142

Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency

Q37348467

The challenge of finding a cure for HIV infection

Q37407598

HIV reservoirs, latency, and reactivation: prospects for eradication

Q37609623

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

Q37615893

Curing HIV: Pharmacologic approaches to target HIV-1 latency

Q37645582

Role of CD27/CD70 pathway of activation in immunity and tolerance

Q37779170

HIV reservoirs: the new frontier.

Q37853874

Control of HIV latency by epigenetic and non-epigenetic mechanisms

Q37972643

Production of HIV-1 by resting memory T lymphocytes

Q39027523

Models of HIV-1 persistence in the CD4+ T cell compartment: past, present and future

Q39418995

Endoplasmic reticulum stress-mediated apoptosis of EBV-transformed B cells by cross-linking of CD70 is dependent upon generation of reactive oxygen species and activation of p38 MAPK and JNK pathway

Q39631558

Effect of latent human immunodeficiency virus infection on cell surface phenotype

Q39682575

Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction

Q39712159

Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line

Q40198849

Discovering regulated networks during HIV-1 latency and reactivation

Q40210426

Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease

Q40382580

Primary cell model for activation-inducible human immunodeficiency virus

Q42093067

Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency.

Q42200917

Prevalence and predictive value of intermittent viremia with combination hiv therapy

Q43670221

Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance

Q43757786

Comparative longitudinal studies of HERV-K and HIV-1 RNA titers in HIV-1-infected patients receiving successful versus unsuccessful highly active antiretroviral therapy

Q44327519

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma

Q44941158

Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.

Q45923645

A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.

Q47608492

Prevention of rejection with BTI-322 after renal transplantation (results at 9 months).

Q47620150

BTI-322 for acute rejection after renal transplantation

Q47620159

BTI-322 for induction therapy after renal transplantation: a randomized study

Q47624463

Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.

Q47720049

Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents

Q47870096

HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology

Q47956025

EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

Q51764521

An in vitro system to model the establishment and reactivation of HIV-1 latency.

Q51960585

CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency.

Q51971372

A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes.

Q51980078

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

Q52013233

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.

Q55239617

An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein

Q58960509

Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes

Q68318303

Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice

Q71616319

Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells

Q72372371

Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells

Q73077376

Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1

Q73615689

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

HIV

Q15787

P304

page(s)

9148-9158

P577

publication date

2013-06-12

P1433

published in

Journal of Virology

Q1251128

P1476

title

High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects

P478

volume

Reverse relations

cites work (P2860)

Q90594756	Barriers for HIV Cure: The Latent Reservoir
Q57811386	CD32 Expression is not Associated to HIV-DNA content in CD4 cell subsets of individuals with Different Levels of HIV Control
Q89787445	CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency
Q89863542	CD4+CD38+ central memory T cells contribute to HIV persistence in HIV-infected individuals on long-term ART
Q36827134	Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
Q89620873	Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
Q59076530	Descours et al. reply
Q35176166	Dynamics of HIV latency and reactivation in a primary CD4+ T cell model
Q35252186	Eradicating HIV-1 infection: seeking to clear a persistent pathogen
Q59136962	Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
Q37636531	Experimental Approaches for Eliminating Latent HIV.
Q37469500	Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice
Q30400491	HIVed, a knowledgebase for differentially expressed human genes and proteins during HIV infection, replication and latency
Q28537694	Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing
Q92177909	Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells
Q37383798	Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics
Q92136409	Impact of Myeloid Reservoirs in HIV Cure Trials
Q37547710	Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation.
Q50726690	MicroRNA expression profiling of Xp11 renal cell carcinoma.
Q58003754	Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4 T Cells
Q35067224	Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells
Q36487031	Paediatric HIV infection in the 'omics era: defining transcriptional signatures of viral control and vaccine responses
Q59361053	Peering into the HIV reservoir
Q100378198	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir
Q90811783	Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa
Q64097650	Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection
Q92300043	Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs
Q47096754	Systems analysis of latent HIV reversal reveals altered stress kinase signaling and increased cell death in infected T cells
Q41929461	T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients
Q38246141	Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions
Q90733079	The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like
Q36053889	The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4(+) T-cells
Q36206925	Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model.